Obesity

Obesity is a chronic, multifactorial metabolic disorder characterized by an excessive accumulation of adipose tissue that impairs health and reduces life expectancy. In veterinary medicine, obesity is defined as a body weight exceeding 30% of the ideal body weight, or a Body Condition Score (BCS) of 8 or 9 on a 9-point scale, or a BCS of 4 or 5 on a 5-point scale. It is the most common nutritional disorder in companion animals, with a prevalence estimated at 30-60% in dogs and cats in developed countries. Obesity is not merely a cosmetic issue; it is a pathological state that predisposes to numerous comorbidities, including insulin resistance, type 2 diabetes mellitus (especially in cats), dyslipidemia, hypertension, orthopedic diseases (e.g., osteoarthritis, cruciate ligament rupture), respiratory compromise (e.g., brachycephalic airway syndrome exacerbation), cardiovascular disease, urinary tract disorders (e.g., feline lower urinary tract disease), certain neoplasms (e.g., transitional cell carcinoma, mammary tumors), and decreased immune function. The pathophysiology involves a complex interplay of genetic, environmental, neuroendocrine, and inflammatory factors, with adipose tissue acting as an active endocrine organ secreting adipokines (e.g., leptin, adiponectin, resistin, tumor necrosis factor-alpha, interleukin-6) that modulate metabolism, inflammation, and appetite regulation. Obesity management requires a multimodal approach including dietary modification, controlled weight loss, increased physical activity, behavioral changes, and, in some cases, pharmacological intervention. The goal is to achieve a gradual, sustainable weight loss (typically 1-2% of body weight per week) to minimize lean body mass loss and prevent rebound weight gain.

The etiology of obesity is multifactorial, involving an imbalance between energy intake and energy expenditure, but with significant contributions from genetic, environmental, and endocrine factors. Primary causes include: 1) Excessive caloric intake: overfeeding, high-calorie diets, frequent treats, table scraps, and free-choice feeding. 2) Sedentary lifestyle: lack of physical activity, indoor confinement, and owner inactivity. 3) Genetic predisposition: certain breeds are more prone to obesity, such as Labrador Retrievers, Golden Retrievers, Beagles, Cocker Spaniels, Dachshunds, Shetland Sheepdogs, and mixed-breed dogs; in cats, domestic shorthair and longhair breeds are overrepresented. Specific genetic mutations have been identified, such as in the melanocortin-4 receptor (MC4R) gene in Labrador Retrievers, which is associated with increased food motivation and obesity. 4) Endocrine disorders: hypothyroidism (dogs), hyperadrenocorticism (Cushing's syndrome), insulinoma, and growth hormone deficiency can lead to weight gain. 5) Medications: chronic glucocorticoid therapy, progestins, and some anticonvulsants (e.g., phenobarbital) can cause weight gain. 6) Neutering: gonadectomy reduces metabolic rate and increases appetite, leading to weight gain if caloric intake is not adjusted. 7) Age: middle-aged animals (5-10 years) are at higher risk. 8) Sex: females are more commonly affected than males. 9) Environmental factors: single-pet households, owner overindulgence, and lack of routine exercise. 10) Psychological factors: stress, anxiety, or boredom can lead to overeating in some animals. The underlying molecular triggers involve dysregulation of appetite-regulating hormones (leptin, ghrelin, neuropeptide Y, pro-opiomelanocortin), impaired insulin signaling, and chronic low-grade inflammation in adipose tissue.

Obesity is a global epidemic in companion animals. Prevalence studies report that 30-60% of dogs and cats in developed countries are overweight or obese. In the United States, the Association for Pet Obesity Prevention (APOP) surveys indicate that approximately 56% of dogs and 60% of cats are overweight or obese. In Europe, similar figures are reported, with some countries showing up to 50% prevalence. Breed predispositions: In dogs, Labrador Retrievers, Golden Retrievers, Beagles, Cocker Spaniels, Dachshunds, Shetland Sheepdogs, and mixed breeds are at higher risk. In cats, domestic shorthair and longhair breeds are more commonly affected, with no strong breed predilection. Age: Middle-aged animals (5-10 years) are at highest risk, with a peak around 6-8 years. Sex: Females are more likely to be obese than males, particularly after neutering. Neutering increases the risk of obesity by 2-3 times in both dogs and cats, due to decreased metabolic rate and increased appetite. Geographic variation: Obesity is more prevalent in urban areas and in households where owners are overweight or have a lower level of education. Seasonality: Weight gain is more common in winter months due to reduced physical activity. There is no significant infectious or seasonal pattern, but environmental factors such as overfeeding during holidays (e.g., Thanksgiving, Christmas) can contribute. The economic impact is substantial, with increased healthcare costs for obesity-related comorbidities.

The pathophysiology of obesity is complex and involves a chronic positive energy balance leading to adipocyte hypertrophy and hyperplasia. Adipose tissue is not an inert storage depot but an active endocrine organ that secretes a variety of adipokines and cytokines. Key mechanisms include: 1) Energy homeostasis dysregulation: The hypothalamus integrates peripheral signals (leptin, insulin, ghrelin, peptide YY) to regulate appetite and energy expenditure. In obesity, leptin resistance develops, leading to impaired satiety signaling and continued overeating. 2) Adipocyte dysfunction: Hypertrophied adipocytes become hypoxic, leading to necrosis and infiltration by macrophages, which release pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta). This results in chronic low-grade systemic inflammation. 3) Insulin resistance: Adipose tissue releases free fatty acids (FFAs) and pro-inflammatory cytokines that interfere with insulin receptor signaling, leading to decreased glucose uptake in muscle and adipose tissue, and increased hepatic gluconeogenesis. This predisposes to type 2 diabetes mellitus, especially in cats. 4) Dyslipidemia: Increased FFA flux to the liver promotes hepatic triglyceride accumulation (hepatic lipidosis) and altered lipoprotein metabolism, leading to hypercholesterolemia and hypertriglyceridemia. 5) Cardiovascular effects: Obesity increases blood volume and cardiac output, leading to hypertension, left ventricular hypertrophy, and increased risk of congestive heart failure. 6) Respiratory compromise: Excess fat deposition in the thoracic and abdominal regions restricts diaphragmatic movement, leading to decreased lung compliance and increased work of breathing. This exacerbates brachycephalic airway syndrome and can lead to exercise intolerance. 7) Orthopedic stress: Excess body weight places increased mechanical stress on joints, accelerating the progression of osteoarthritis and increasing the risk of cruciate ligament rupture. 8) Endocrine alterations: Obesity is associated with altered thyroid hormone metabolism (decreased T3 and T4), increased cortisol secretion, and altered growth hormone axis. 9) Urinary system: In cats, obesity is a risk factor for feline lower urinary tract disease (FLUTD) and urinary incontinence. 10) Neoplasia: Obesity is associated with an increased risk of certain cancers, including transitional cell carcinoma of the bladder, mammary tumors, and oral melanoma. The systemic inflammatory state and altered hormone levels contribute to tumorigenesis. 11) Immune dysfunction: Obesity impairs cell-mediated immunity, increasing susceptibility to infections and delaying wound healing. 12) Thermoregulation: Excess fat acts as an insulator, impairing heat dissipation and increasing risk of heat stroke.

Intrinsic factors: 1) Genetics: Breed predispositions as mentioned; specific gene mutations (e.g., MC4R in Labradors) increase food motivation. 2) Age: Middle-aged animals are more prone due to decreased metabolic rate and activity. 3) Sex: Females are more likely to be obese, especially after neutering. 4) Neutering: Gonadectomy reduces metabolic rate by 10-15% and increases appetite, leading to weight gain if caloric intake is not adjusted. 5) Endocrine disorders: Hypothyroidism, hyperadrenocorticism, insulinoma, and growth hormone deficiency can cause weight gain. 6) Metabolic rate: Individual variations in basal metabolic rate and energy expenditure. Extrinsic factors: 1) Diet: High-calorie diets, excessive treats, table scraps, and free-choice feeding. 2) Feeding practices: Inconsistent feeding schedules, large portion sizes, and lack of portion control. 3) Physical activity: Sedentary lifestyle, lack of exercise, and indoor confinement. 4) Owner behavior: Overindulgence, lack of awareness of ideal body condition, and anthropomorphizing pets. 5) Environmental factors: Single-pet households, absence of other pets to play with, and lack of outdoor access. 6) Medications: Chronic glucocorticoid therapy, progestins, and phenobarbital can cause weight gain. 7) Concurrent diseases: Orthopedic pain, respiratory disease, and cardiovascular disease can limit exercise, leading to weight gain. 8) Psychological factors: Stress, anxiety, or boredom can lead to overeating. 9) Socioeconomic factors: Owners with lower income or education may be more likely to overfeed. 10) Previous episodes of weight loss: Rapid weight loss followed by rebound weight gain can alter metabolic set points.

Clinical signs of obesity are often subtle and may be overlooked by owners. They include: 1) General: Increased body weight, visible fat deposits over the thorax, abdomen, and lumbar area, and a pendulous abdomen. 2) Body Condition Score (BCS) of 8 or 9 on a 9-point scale, or 4 or 5 on a 5-point scale. 3) Exercise intolerance: Reluctance to exercise, tiring easily, and excessive panting. 4) Respiratory signs: Increased respiratory effort, especially in brachycephalic breeds, and sleep apnea. 5) Orthopedic signs: Lameness, stiffness, difficulty rising, and reluctance to jump or climb stairs, due to osteoarthritis or cruciate ligament disease. 6) Dermatological signs: Skin folds, intertrigo, poor coat quality, and increased risk of skin infections. 7) Cardiovascular signs: Tachycardia, hypertension, and signs of congestive heart failure in severe cases. 8) Endocrine signs: Polyuria, polydipsia, and polyphagia if diabetes mellitus or hyperadrenocorticism is present. 9) Gastrointestinal signs: Constipation, flatulence, and increased risk of pancreatitis. 10) Urinary signs: In cats, increased risk of FLUTD, including hematuria, dysuria, and urethral obstruction. 11) Reproductive signs: Decreased fertility, irregular estrous cycles, and increased risk of dystocia. 12) Neoplastic signs: Increased risk of certain tumors, which may present as palpable masses. 13) Behavioral changes: Lethargy, depression, and decreased interaction with owners. 14) Heat intolerance: Increased risk of heat stroke due to impaired thermoregulation. 15) Decreased immune function: Increased susceptibility to infections and delayed wound healing. In severe cases, obesity can lead to respiratory distress, especially in cats with hepatic lipidosis, and can be life-threatening.

Differential diagnoses for obesity include: 1) Hypothyroidism: Common in dogs, especially middle-aged to older breeds like Golden Retrievers, Labrador Retrievers, and Doberman Pinschers. Clinical signs include weight gain, lethargy, hair loss, and cold intolerance. Diagnosis is based on low total T4, low free T4, and elevated TSH. 2) Hyperadrenocorticism (Cushing's syndrome): Common in dogs, especially Poodles, Dachshunds, and Boxers. Signs include weight gain, pot-bellied appearance, polyuria, polydipsia, polyphagia, and alopecia. Diagnosis via ACTH stimulation test or low-dose dexamethasone suppression test. 3) Insulinoma: Rare pancreatic tumor causing hypoglycemia, which can lead to increased appetite and weight gain. Diagnosis via fasting blood glucose and insulin levels. 4) Diabetes mellitus: Especially in cats, obesity is a risk factor, but diabetes can cause weight loss despite polyphagia. Diagnosis via persistent hyperglycemia and glucosuria. 5) Growth hormone deficiency (hypopituitarism): Rare, can cause weight gain in young animals. 6) Cushing's disease in cats: Rare, but can cause weight gain and skin fragility. 7) Fluid retention (ascites, edema): Can cause weight gain, but is usually accompanied by other signs such as abdominal distension and dyspnea. 8) Neoplasia: Some tumors can cause weight gain due to hormonal secretion or mechanical effects. 9) Pregnancy: In intact females, weight gain is expected. 10) Medications: Chronic glucocorticoid or progestin therapy can cause weight gain. 11) Genetic disorders: Prader-Willi syndrome in humans, but not recognized in animals. 12) Hypothalamic obesity: Rare, due to hypothalamic lesions. To differentiate, a thorough history, physical examination, and diagnostic testing (e.g., thyroid panel, adrenal function tests, blood glucose, insulin levels) are essential.

The diagnostic approach to obesity involves: 1) History and physical examination: Obtain a detailed dietary history, including type and amount of food, treats, and table scraps. Assess activity level and any underlying medical conditions. Perform a thorough physical examination, including body weight, Body Condition Score (BCS) using a 9-point or 5-point scale, and Muscle Condition Score (MCS). Measure waist circumference and assess fat distribution. 2) Rule out underlying endocrinopathies: If clinical signs suggest hypothyroidism (e.g., lethargy, hair loss), perform a baseline serum total T4, free T4 by equilibrium dialysis, and canine TSH. If hyperadrenocorticism is suspected (e.g., pot-bellied appearance, polyuria, polydipsia), perform an ACTH stimulation test or low-dose dexamethasone suppression test. In cats, rule out diabetes mellitus with blood glucose and fructosamine levels. 3) Laboratory testing: Complete blood count (CBC), serum biochemistry profile, and urinalysis to assess for comorbidities such as diabetes, hyperlipidemia, and hepatic disease. 4) Imaging: Thoracic radiographs to assess for cardiomegaly or respiratory disease; abdominal ultrasound to evaluate for adrenal gland enlargement or hepatic lipidosis. 5) Body composition analysis: Dual-energy X-ray absorptiometry (DEXA) is the gold standard but is rarely used in practice. Bioelectrical impedance analysis (BIA) and deuterium dilution are research tools. 6) Assessment of comorbidities: Blood pressure measurement, echocardiography if cardiac disease is suspected, and orthopedic examination for osteoarthritis. 7) Weight loss plan: Once obesity is confirmed and underlying diseases are ruled out or managed, develop a structured weight loss program. 8) Monitoring: Regular weigh-ins every 2-4 weeks to assess progress and adjust caloric intake as needed.

Laboratory findings in obesity are often nonspecific but may reveal underlying comorbidities. Hematology: CBC is usually within normal limits, but may show mild leukocytosis due to chronic inflammation. Serum biochemistry: 1) Hyperlipidemia: Elevated cholesterol and triglycerides are common, especially in dogs. 2) Hyperglycemia: Mild to moderate hyperglycemia may be present, especially in cats with insulin resistance. 3) Elevated liver enzymes: Alanine aminotransferase (ALT) and alkaline phosphatase (ALP) may be mildly elevated due to hepatic lipidosis or fatty liver. 4) Hyperinsulinemia: Fasting insulin levels may be elevated, indicating insulin resistance. 5) Elevated cortisol: In dogs with hyperadrenocorticism, cortisol levels may be elevated. 6) Thyroid function: Total T4 may be low in hypothyroidism, but free T4 and TSH are more specific. Urinalysis: May show glucosuria if diabetes mellitus is present. Proteinuria may be present if hypertension or renal disease is concurrent. Blood gas analysis: May show respiratory acidosis in severe obesity due to hypoventilation. Specific biomarkers: 1) Leptin: Elevated in obesity, but not routinely measured. 2) Adiponectin: Decreased in obesity, but not routinely measured. 3) Inflammatory markers: C-reactive protein (CRP) may be elevated in dogs. 4) NT-proBNP: May be elevated if cardiac disease is present. 5) SDMA: May be elevated if renal disease is present. 6) Fructosamine: In cats, elevated if diabetes mellitus is present. 7) Insulin-like growth factor-1 (IGF-1): May be altered in growth hormone disorders. Serology/PCR: Not typically indicated unless infectious causes are suspected. Endocrinological assays: ACTH stimulation test, low-dose dexamethasone suppression test, thyroid panel, and insulin/glucose ratio are used to rule out endocrinopathies.

Imaging is not routinely required for the diagnosis of obesity, but it is useful to assess comorbidities. Radiography: Thoracic radiographs may reveal cardiomegaly, pulmonary changes, or pleural effusion in cases of heart failure. Abdominal radiographs may show hepatomegaly, increased abdominal fat, and organomegaly. In obese animals, radiographs may be technically challenging due to excessive fat. Ultrasonography: Abdominal ultrasound can assess liver echogenicity (diffuse hyperechogenicity suggests hepatic lipidosis), adrenal gland size (enlargement in hyperadrenocorticism), and pancreatic changes. Echocardiography: May be indicated if cardiac disease is suspected; obesity can cause left ventricular hypertrophy and diastolic dysfunction. Computed Tomography (CT): Can quantify visceral fat and assess for adrenal tumors or other masses. Magnetic Resonance Imaging (MRI): Used for research purposes to assess body composition. Endoscopy: Not indicated for obesity itself, but may be used to evaluate gastrointestinal signs. Fluoroscopy: Not typically used. In practice, imaging is used to rule out underlying diseases that may contribute to weight gain, such as hyperadrenocorticism (adrenal enlargement) or hypothyroidism (no specific imaging findings).

Cytology and histopathology are not typically required for the diagnosis of obesity. However, if a mass is detected, fine-needle aspiration (FNA) may be performed to rule out neoplasia. Histopathology of adipose tissue may show adipocyte hypertrophy and hyperplasia, with infiltration of macrophages (crown-like structures) indicating chronic inflammation. In cases of hepatic lipidosis, liver biopsy would show marked vacuolization of hepatocytes with fat. In cases of hypothyroidism, thyroid biopsy is rarely performed. In general, these diagnostic modalities are reserved for specific differential diagnoses.

The treatment of obesity is a multimodal approach that requires a long-term commitment from the owner and veterinary team. The primary goal is to achieve a gradual weight loss of 1-2% of body weight per week, with a target of reaching ideal body weight over 3-6 months. Treatment components include: 1) Dietary modification: Prescribe a therapeutic weight loss diet that is high in protein, high in fiber, and low in fat and calories. These diets are designed to promote satiety while maintaining lean body mass. Examples include Hill's Prescription Diet Metabolic, Royal Canin Veterinary Diet Satiety Support, and Purina Pro Plan Veterinary Diets OM Overweight Management. The daily caloric intake should be calculated based on the ideal body weight, using the resting energy requirement (RER) formula: RER (kcal/day) = 70 x (ideal body weight in kg)^0.75. For weight loss, feed 60-70% of RER for the ideal body weight. Divide the daily amount into two or more meals. Avoid treats and table scraps; if treats are given, they should be low-calorie and accounted for in the daily caloric intake. 2) Exercise: Gradually increase physical activity. For dogs, start with short, low-impact walks and gradually increase duration and intensity. For cats, encourage play with interactive toys, laser pointers, and climbing structures. Aim for at least 30 minutes of exercise per day for dogs, and 15-30 minutes for cats. 3) Behavioral modification: Establish a consistent feeding schedule, measure food portions, and avoid free-choice feeding. Use puzzle feeders to slow down eating and increase satiety. 4) Pharmacological intervention: In some cases, medications may be used to aid weight loss. In dogs, the only approved drug is dirlotapide (Slentrol), a microsomal triglyceride transfer protein inhibitor that reduces fat absorption. However, it has been withdrawn from the market in some countries. Other drugs used off-label include: - Leptin analogs: Not available for veterinary use. - Cannabinoid receptor antagonists: Not approved. - Glucagon-like peptide-1 (GLP-1) receptor agonists: E.g., liraglutide, used in humans, but not approved for animals. - In cats, no weight loss drugs are approved. 5) Management of underlying diseases: If hypothyroidism or hyperadrenocorticism is diagnosed, treat accordingly. 6) Surgical intervention: In extreme cases, bariatric surgery has been attempted but is not recommended due to high risk. 7) Supportive care: Monitor for complications such as hepatic lipidosis in cats during rapid weight loss. Ensure adequate hydration and provide joint supplements (e.g., omega-3 fatty acids, glucosamine) if osteoarthritis is present. 8) Owner education: Provide clear instructions on feeding, exercise, and monitoring. Schedule regular weigh-ins and adjust the plan as needed.

The prognosis for obesity is generally good if the condition is managed appropriately. With a structured weight loss program, most animals can achieve their ideal body weight within 6-12 months. However, long-term success depends on owner compliance and lifestyle changes. Negative prognostic indicators include: 1) Severe obesity (BCS 9/9) at presentation. 2) Presence of comorbidities such as diabetes mellitus, hypertension, or orthopedic disease. 3) Lack of owner compliance with dietary and exercise recommendations. 4) Underlying endocrinopathies that are not well controlled. 5) Rapid weight loss leading to hepatic lipidosis in cats. 6) Rebound weight gain after initial loss. Mortality rates are not directly attributed to obesity, but obesity reduces life expectancy by up to 2.5 years in dogs. Weight loss improves quality of life, reduces pain, and resolves many comorbidities. For example, in cats with diabetes mellitus, weight loss can lead to remission in up to 50-80% of cases. In dogs with osteoarthritis, weight loss significantly improves mobility and reduces pain. Regular monitoring and long-term maintenance are essential to prevent recurrence.

Follow-up is critical for successful weight management. The following schedule is recommended: 1) Initial assessment: At the start of the weight loss program, perform a complete physical examination, BCS, MCS, and baseline laboratory tests. 2) Recheck every 2-4 weeks: Weigh the animal at each visit, measure BCS, and assess body measurements (e.g., waist circumference). Adjust caloric intake based on rate of weight loss. If weight loss is too rapid (>2% per week), increase caloric intake slightly; if too slow (<0.5% per week), decrease caloric intake by 10-20%. 3) Monthly: Monitor for any adverse effects, such as lethargy, weakness, or gastrointestinal upset. In cats, monitor for signs of hepatic lipidosis (e.g., anorexia, vomiting, jaundice). 4) Every 3 months: Repeat laboratory tests (CBC, biochemistry, urinalysis) to assess for metabolic changes. 5) Once ideal body weight is achieved: Transition to a weight maintenance diet and calculate maintenance calories (typically 1.0-1.2 x RER for the ideal weight). Continue to monitor weight monthly for the first 6 months, then every 3-6 months thereafter. 6) Long-term: Encourage regular exercise and healthy feeding habits. Provide ongoing support and education to the owner. 7) If the animal has comorbidities, follow up accordingly (e.g., blood glucose monitoring for diabetics, blood pressure checks for hypertensives). 8) Document progress with photographs and body measurements to motivate the owner.

Pearls: 1) Always calculate the ideal body weight based on breed standards and body frame, not just the owner's perception. 2) Use a consistent BCS system (e.g., 9-point) and document it at every visit. 3) Emphasize the importance of measuring food portions with a standard measuring cup or kitchen scale. 4) Recommend high-protein, high-fiber diets to promote satiety and preserve lean muscle mass. 5) Encourage slow weight loss (1-2% per week) to avoid hepatic lipidosis in cats and to maintain muscle mass. 6) Incorporate exercise gradually to avoid injury. 7) Use positive reinforcement and set realistic goals with the owner. 8) Consider using a weight loss app or diary to track progress. 9) Address any underlying medical conditions that may contribute to weight gain. 10) Celebrate milestones to keep the owner motivated. Pitfalls: 1) Failing to rule out underlying endocrinopathies before starting a weight loss program. 2) Setting unrealistic weight loss goals (e.g., >2% per week) leading to muscle loss or hepatic lipidosis. 3) Not adjusting caloric intake based on weight loss progress. 4) Allowing unlimited treats or table scraps, which can sabotage the diet. 5) Neglecting to monitor body condition score and muscle condition score. 6) Recommending a very low-calorie diet without veterinary supervision, which can lead to nutritional deficiencies. 7) Ignoring the owner's lifestyle and ability to comply with exercise recommendations. 8) Failing to provide long-term follow-up and support, leading to rebound weight gain. 9) Using weight loss drugs without proper monitoring. 10) Not addressing pain from osteoarthritis, which may limit exercise.

Pharmacological interventions for obesity are limited in veterinary medicine. The following drugs are used or have been used: 1) Dirlotapide (Slentrol) - Dogs: This is a microsomal triglyceride transfer protein inhibitor that reduces intestinal fat absorption. Dosage: Initial dose 0.01 mg/kg PO once daily for 14 days, then increase to 0.02 mg/kg PO once daily for 14 days, then titrate up to a maximum of 0.2 mg/kg PO once daily. Administer with food. Monitor for vomiting, diarrhea, and decreased appetite. It is contraindicated in cats and in dogs with liver disease. It has been withdrawn from the market in some countries due to adverse effects. 2) Mitratapide (Yarvitan) - Dogs: Another microsomal triglyceride transfer protein inhibitor. Dosage: 0.5 mg/kg PO once daily for 7 days, then 1 mg/kg PO once daily for 7 days, then 1.5 mg/kg PO once daily for 7 days, then 2 mg/kg PO once daily for 7 days, then 2.5 mg/kg PO once daily for 7 days, then 3 mg/kg PO once daily for 7 days. Administer with food. Monitor for vomiting and diarrhea. Not approved in all countries. 3) Leptin analogs: Not available for veterinary use. 4) GLP-1 receptor agonists (e.g., liraglutide): Used in humans, but not approved for animals. 5) Cannabinoid receptor antagonists (e.g., rimonabant): Withdrawn from human market due to psychiatric side effects. 6) Sibutramine: Withdrawn from human market. 7) Orlistat: A lipase inhibitor used in humans; not approved for animals, but has been used experimentally in dogs. Dosage: 2.5-5 mg/kg PO q8h with meals. May cause gastrointestinal side effects. 8) In cats, no weight loss drugs are approved. 9) For underlying conditions: - Hypothyroidism: Levothyroxine (Soloxine) 0.02 mg/kg PO q12h, adjust based on T4 levels. - Hyperadrenocorticism: Trilostane (Vetoryl) 2-6 mg/kg PO q24h, adjust based on ACTH stimulation test. - Diabetes mellitus: Insulin therapy (e.g., glargine in cats, NPH in dogs) as per standard protocols. 10) Supportive medications: - Omega-3 fatty acids (e.g., fish oil) 100-200 mg/kg PO q24h for anti-inflammatory effects. - Glucosamine/chondroitin for osteoarthritis. - Appetite suppressants: Not recommended. All drugs should be used with caution, and dosages should be adjusted for renal or hepatic impairment. Contraindications and drug interactions should be reviewed before prescribing.

Key evidence-based literature on obesity in dogs and cats includes: 1) The Association for Pet Obesity Prevention (APOP) surveys provide prevalence data and highlight the need for owner education. 2) A landmark study by German et al. (2006) demonstrated that weight loss in dogs with osteoarthritis significantly improved lameness and mobility. 3) A study by Tvarijonaviciute et al. (2012) showed that weight loss in dogs reduced serum inflammatory markers (CRP, TNF-alpha). 4) In cats, a study by Zoran (2010) emphasized the importance of high-protein, low-carbohydrate diets for weight loss and diabetes remission. 5) The ACVIM consensus statement on obesity (2015) provides guidelines for diagnosis and management. 6) A meta-analysis by Bissot et al. (2010) evaluated the efficacy of dirlotapide in dogs, showing significant weight loss but with gastrointestinal side effects. 7) A study by Laflamme (2006) established the use of BCS and MCS in clinical practice. 8) Research on the genetic basis of obesity in Labrador Retrievers (Raffan et al., 2016) identified the MC4R mutation. 9) A study by Bjornvad et al. (2019) investigated the effects of neutering on energy requirements and weight gain in dogs. 10) The WSAVA Nutritional Assessment Guidelines (2011) provide a framework for dietary assessment. 11) A randomized controlled trial by Flanagan et al. (2017) compared different weight loss diets in dogs, showing that high-protein, high-fiber diets were more effective. 12) In cats, a study by Verbrugghe et al. (2012) evaluated the effects of weight loss on insulin sensitivity. 13) The European Pet Obesity Clinic (EPOC) has published guidelines for weight management. 14) A study by Michel et al. (2011) assessed owner compliance and barriers to weight loss. 15) Long-term follow-up studies show that weight maintenance is challenging, with a high rate of rebound weight gain. These studies support the multimodal approach to obesity management, emphasizing dietary modification, exercise, and behavioral changes.